Exelixis’ Cabometyx R&D On Track Despite Pivotal Kidney Cancer Setback

The US firm’s Cabometyx has missed the mark in combination with Roche’s Tecentriq in a challenging kidney cancer setting, but analysts argue the setback is minimal as they highlight two major readouts coming this year.